Biofrontera Inc. provided revenue guidance for the third quarter and nine months of 2023 and re-affirmed revenue guidance for the year 2023. Revenues for the third quarter of 2023 are anticipated to be in the range of approximately $8.7 million to $9.0 million, an increase of approximately 101% to 108% compared with the third quarter of 2022.

Revenues for the first nine months of 2023 are anticipated to be in the range of approximately $23.3 million to $23.6 million, representing growth of approximately 25% to 27% compared with the first nine months of 2022.

The company affirmed its previously announced expectations for full-year 2023 revenue growth to be at least 25% compared with 2022.